{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T14:17:45Z","timestamp":1793542665919,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study investigated the occurrence of subsequent malignancies (SM) in adult patients with severe aplastic anemia (SAA) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to address the lack of large-scale, long-term data on this complication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort analysis of 376 adult patients with SAA who underwent allo-HSCT between 2002 and 2021 at a single center was conducted. The incidence, risk factors, and survival impact of SM were also examined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the follow-up period, 31 cases of SM (8.2%) were identified. Approximately one-third (32.3%) of SM cases were hematologic malignancies, including post-transplant lymphoproliferative disorder (16.1%), myelodysplastic neoplasm (6.5%), and acute myeloid leukemia (3.2%). Solid tumors accounted for 67.7% of cases, with thyroid cancer being the most prevalent (25.8%). The 15-year cumulative incidence of SM was 11.2%, and the hazard ratio for overall survival according to the development of SM was 16.25 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). High-dose total body irradiation (TBI), anti-thymocyte globulin (ATG), and moderate-to-severe chronic graft-versus-host disease (GVHD) were identified as significant risk factors for subsequent malignancy. Post-transplant SAA patients exhibited a 3.54-fold higher observed cancer incidence than the expected incidence calculated from the age-, sex-, and calendar year-matched general population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>SM is a significant long-term complication in patients with posttransplant SAA and has a substantial survival impact. Patients receiving high-dose TBI or ATG, and those with moderate-to-severe chronic GVHD, require vigilant long-term monitoring.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s44313-024-00046-2","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T07:40:49Z","timestamp":1735026049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence and outcomes of subsequent malignancy after allogeneic hematopoietic stem cell transplantation in adult patients with severe aplastic anemia"],"prefix":"10.1007","volume":"59","author":[{"given":"Daehun","family":"Kwag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"46_CR1","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra1413485","volume":"379","author":"NS Young","year":"2018","unstructured":"Young NS. Aplastic Anemia. N Engl J Med. 2018;379:1643\u201356.","journal-title":"N Engl J Med"},{"key":"46_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3904\/kjim.2014.29.6.713","volume":"29","author":"SH Shin","year":"2014","unstructured":"Shin SH, Lee SE, Lee JW. Recent advances in treatment of aplastic anemia. Korean J Intern Med. 2014;29:713\u201326.","journal-title":"Korean J Intern Med"},{"key":"46_CR3","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/bloodadvances.2018021162","volume":"2","author":"GE Georges","year":"2018","unstructured":"Georges GE, Doney K, Storb R. Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. Blood Adv. 2018;2:2020\u20138.","journal-title":"Blood Adv"},{"key":"46_CR4","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1182\/blood-2017-03-725671","volume":"130","author":"S Bhatia","year":"2017","unstructured":"Bhatia S, Armenian SH, Landier W. How I monitor long-term and late effects after blood or marrow transplantation. Blood. 2017;130:1302\u201314.","journal-title":"Blood"},{"key":"46_CR5","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1182\/blood.V87.9.3633.bloodjournal8793633","volume":"87","author":"S Bhatia","year":"1996","unstructured":"Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87:3633\u20139.","journal-title":"Blood"},{"key":"46_CR6","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1016\/j.bbmt.2011.10.005","volume":"18","author":"G Soci\u00e9","year":"2012","unstructured":"Soci\u00e9 G, Baker KS, Bhatia S. Subsequent malignant neoplasms after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:S139\u201350.","journal-title":"Biol Blood Marrow Transplant"},{"key":"46_CR7","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1200\/JCO.2003.05.108","volume":"21","author":"KS Baker","year":"2003","unstructured":"Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21:1352\u20138.","journal-title":"J Clin Oncol"},{"key":"46_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.critrevonc.2005.03.014","volume":"56","author":"D Ghelani","year":"2005","unstructured":"Ghelani D, Saliba R, Lima M. Secondary malignancies after hematopoietic stem cell transplantation. Crit Rev Oncol Hematol. 2005;56:115\u201326.","journal-title":"Crit Rev Oncol Hematol"},{"key":"46_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4274\/balkanmedj.galenos.2023.2022-10-56","volume":"40","author":"HL Liu","year":"2023","unstructured":"Liu HL, Chen YH, Chung CH, et al. Risk of secondary malignancies in hematopoietic stem cell transplantation recipients: a nationwide population-based study in Taiwan. Balkan Med J. 2023;40:131\u20138.","journal-title":"Balkan Med J"},{"key":"46_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/bloodadvances.2020003910","volume":"6","author":"L Nunez","year":"2022","unstructured":"Nunez L, Abedin T, Naqvi S, et al. Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation. Blood Adv. 2022;6:767\u201373.","journal-title":"Blood Adv"},{"key":"46_CR11","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1182\/bloodadvances.2022007941","volume":"7","author":"H Rafii","year":"2023","unstructured":"Rafii H, Ruggeri A, Kenzey C, et al. Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe. Blood Adv. 2023;7:1976\u201386.","journal-title":"Blood Adv"},{"key":"46_CR12","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3324\/haematol.2017.169862","volume":"102","author":"K Vaht","year":"2017","unstructured":"Vaht K, G\u00f6ransson M, Carlson K, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000\u20132011. Haematologica. 2017;102:1683\u201390.","journal-title":"Haematologica"},{"key":"46_CR13","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/s41409-019-0696-9","volume":"55","author":"SS Park","year":"2020","unstructured":"Park SS, Min GJ, Park S, et al. Excellent outcomes of hematopoietic stem cell transplantation with total nodal irradiation and antithymocyte globulin conditioning in severe aplastic anemia with advanced age and\/or severe comorbidity. Bone Marrow Transplant. 2020;55:1447\u201350.","journal-title":"Bone Marrow Transplant"},{"key":"46_CR14","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/s41409-020-0820-x","volume":"55","author":"SH Shin","year":"2020","unstructured":"Shin SH, Park SS, Yoon JH, et al. Comparison of HLA-matched sibling and unrelated donor transplantation in adult patients with acquired severe aplastic anemia. Bone Marrow Transplant. 2020;55:1570\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"46_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM198203183061105","volume":"306","author":"BM Camitta","year":"1982","unstructured":"Camitta BM, Storb R, Thomas ED. Aplastic anemia (first of two parts): pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med. 1982;306:645\u201352.","journal-title":"N Engl J Med"},{"key":"46_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22:4\u201310.","journal-title":"Biol Blood Marrow Transplant"},{"key":"46_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389-401.e1.","journal-title":"Biol Blood Marrow Transplant"},{"key":"46_CR18","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute, 2023. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Accessed 30 Sept 2024."},{"key":"46_CR19","unstructured":"Statistics Korea. Number of cancers by sex and age (5 years) for 24 cancers, incidence rates, 2024.\u00a0https:\/\/kosis.kr\/statHtml\/statHtml.do?conn_path=K2&tblId=DT_1B34E01&orgId=101. Accessed 30 Sept 2024."},{"key":"46_CR20","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3324\/haematol.2013.100784","volume":"99","author":"J Delgado","year":"2014","unstructured":"Delgado J, Pereira A, Villamor N, L\u00f3pez-Guillermo A, Rozman C. Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica. 2014;99:1410\u201320.","journal-title":"Haematologica"},{"key":"46_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/mpr.124","volume":"11","author":"LR Schultz","year":"2002","unstructured":"Schultz LR, Peterson EL, Breslau N. Graphing survival curve estimates for time-dependent covariates. Int J Methods Psychiatr Res. 2002;11:68\u201374.","journal-title":"Int J Methods Psychiatr Res"},{"key":"46_CR22","first-page":"2208","volume":"94","author":"RE Curtis","year":"1999","unstructured":"Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208\u201316.","journal-title":"Blood"},{"key":"46_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1365-2141.2011.08756.x","volume":"154","author":"NS Majhail","year":"2011","unstructured":"Majhail NS. Secondary cancers following allogeneic haematopoietic cell transplantation in adults. Br J Haematol. 2011;154:301\u201310.","journal-title":"Br J Haematol"},{"key":"46_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/bmt.2013.190","volume":"49","author":"J Sanz","year":"2014","unstructured":"Sanz J, Arango M, Senent L, et al. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Bone Marrow Transplant. 2014;49:397\u2013402.","journal-title":"Bone Marrow Transplant"},{"key":"46_CR25","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1182\/blood-2006-03-011791","volume":"108","author":"CG Brunstein","year":"2006","unstructured":"Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006;108:2874\u201380.","journal-title":"Blood"},{"key":"46_CR26","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/MOH.0000000000000083","volume":"21","author":"RH Rouce","year":"2014","unstructured":"Rouce RH, Louis CU, Heslop HE. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol. 2014;21:476\u201381.","journal-title":"Curr Opin Hematol"},{"key":"46_CR27","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1200\/JCO.2008.20.0857","volume":"27","author":"JS Knight","year":"2009","unstructured":"Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol. 2009;27:3354\u201362.","journal-title":"J Clin Oncol"},{"key":"46_CR28","doi-asserted-by":"publisher","first-page":"i5745","DOI":"10.1136\/bmj.i5745","volume":"355","author":"S Park","year":"2016","unstructured":"Park S, Oh CM, Cho H, et al. Association between screening and the thyroid cancer \u201cepidemic\u201d in South Korea: evidence from a nationwide study. BMJ. 2016;355:i5745.","journal-title":"BMJ"},{"key":"46_CR29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/jjco\/hyn026","volume":"38","author":"KY Yoo","year":"2008","unstructured":"Yoo KY. Cancer control activities in the Republic of Korea. Jpn J Clin Oncol. 2008;38:327\u201333.","journal-title":"Jpn J Clin Oncol"},{"key":"46_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11864-018-0528-y","volume":"19","author":"I Danylesko","year":"2018","unstructured":"Danylesko I, Shimoni A. Second malignancies after hematopoietic stem cell transplantation. Curr Treat Options Oncol. 2018;19:9.","journal-title":"Curr Treat Options Oncol"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-024-00046-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-024-00046-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-024-00046-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T20:09:34Z","timestamp":1735070974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-024-00046-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["46"],"URL":"https:\/\/doi.org\/10.1007\/s44313-024-00046-2","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the Catholic University of Korea (Seoul, Republic of Korea). Approval number: KC24RASI0690. All procedures involving patient participation were conducted in accordance with the Declaration of Helsinki. Since this study was a retrospective review of medical records, there was no risk to the patients, and obtaining consent was impractical. During the review of medical records, personal identifiers that could reveal the participants, such as names and hospital registration numbers, were not recorded; only serial numbers were retained in the research records. Therefore, the Institutional Review Board waived the requirement for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}